Full Text (PDF)
Review Article

Alpha Fetoprotein: Tumor Marker in Gynaecology

Akshay N Jagtap , Alka Patil1 , Akshay N Jagtap2 , Sneha U Sanap3

Author Information

Licence:




Indian Journal of Obstetrics and Gynecology 8(4):p 269-273, October-December 2020. | DOI: http://dx.doi.org/10.21088/ijog.2321.1636.8420.12

How Cite This Article:

Alka Patil, Akshay N Jagtap, Sneha U Sanap. Alpha Fetoprotein: Tumor Marker in Gynaecology. Indian J Obstet Gynecol. 2020;8(4):269–273.


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

Ovarian carcinoma is the fifth most common cause of cancer death. It is the second most common gynecologic malignancy in developed countries and the third most common gynecological cancer. There are several intrinsic problems that render ovarian cancer screening difficult. An optimal screening test has high sensitivity, specificity, patient acceptance. The three screening techniques available for ovarian malignancy are: Pelvic examination, Tumor Marker, TVS. Tumor markers are used to screen for or diagnose malignancies, determine prognosis or monitor therapy. Alpha Fetoprotein is tumour marker for Embryonal Carcinoma, Yolk Sac tumour, Immature Teratoma, Sertoli-Leydigs cell tumour. The concept of preventive oncology has been developed to approach cancer problem at various points in evolution with goal of reducing cancer suffering and death.


References

No records found.


About this article


Cite this article

Alka Patil, Akshay N Jagtap, Sneha U Sanap. Alpha Fetoprotein: Tumor Marker in Gynaecology. Indian J Obstet Gynecol. 2020;8(4):269–273.


Licence:




Received Accepted Published
N/A N/A N/A

DOI: http://dx.doi.org/10.21088/ijog.2321.1636.8420.12

Keywords

Ovarian Cancer; Alpha Fetoprotein; Germ cell tumours; Tumour Markers; Cancer Screening.

Article Level Metrics

Last Updated

Wednesday 17 June 2026, 23:10:35 (IST)


1422

Accesses

3
152
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share